Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia

Korean Journal of Pediatrics

Volumn 56, Issue 8, 2013, Pages 343-350

  Oh, Hyun Jin ^a   Cho, Mun Sung ^a   Lee, Jae Wook ^a   Jang, Pil Sang ^a   Chung, Nack Gyun ^a   Cho, Bin ^a   Kim, Hack Ki ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Allogeneic transplantation; Children; Chronic myelogenous leukemia; Imatinib mesylate

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; DASATINIB; ETOPOSIDE; HYDROXYUREA; IMATINIB;

ABDOMINAL PAIN; ADOLESCENT; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTRANSAMINASEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAPILLEDEMA; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT RESPONSE; URINARY FREQUENCY; VOMITING;

EID: 84881635958     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2013.56.8.343     Document Type: Article

References (28)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330-40.
2. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am 1988;35:765-87.
3. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
4. Druker BJ, Guilhot F, O-Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-17.
5. Hochhaus A, O-Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23:1054-61.
6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
7. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9.
8. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51.
9. Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 2012;53:2430-3.
10. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827-32.
11. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92.
12. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012;119:1821-30.
13. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children-s oncology group phase I consortium. J Clin Oncol 2011;29:839-44.
14. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC, 2008:32-7.
15. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
16. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Ver. 4.0 [Internet]. Bethesda: National Cancer Institute; [cited 2012 Jul 25]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
17. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003;102:1224-31.
18. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2003;32:993-9.
19. Muramatsu H, Takahashi Y, Sakaguchi H, Shimada A, Nishio N, Hama A, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol 2011;93:186-91.
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Colon/rectal cancer. ver. 1. 2010 [Internet]. Fort Wathington: NCCN; c2012 [cited 2012 Aug 27]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
21. Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr 2011;54:111-6.
22. Larson RA, Druker BJ, Guilhot F, O-Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-8.
23. Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 2012;30:200-5.
24. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9.
25. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:5065-71.
26. Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639-46.
27. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012;59:481-4.
28. Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011;159:676-81.